Direkt zum Inhalt
Merck
  • Novel NLRP12 mutations associated with intestinal amyloidosis in a patient diagnosed with common variable immunodeficiency.

Novel NLRP12 mutations associated with intestinal amyloidosis in a patient diagnosed with common variable immunodeficiency.

Clinical immunology (Orlando, Fla.) (2014-07-30)
Stephan Borte, Mehmet Halil Celiksoy, Volker Menzel, Ozan Ozkaya, Fatma Zeynep Ozen, Lennart Hammarström, Alisan Yildiran
ZUSAMMENFASSUNG

Heterozygous mutations in the NLRP12 gene have been found in patients with systemic auto-inflammatory diseases. However, the NLRP12-associated periodic fever syndromes show a wide clinical spectrum, including patients without classical diagnostic symptoms. Here, we report on a 20-year-old female patient diagnosed with common variable immunodeficiency (CVID), who developed intestinal amyloidosis and carried novel compound heterozygous mutations in NLRP12, identified by whole exome and transcriptome sequencing. CVID is a primary immunodeficiency characterized by low serum immunoglobulins, recurrent bacterial infections and development of malignancy, but it also presents with a magnitude of autoimmune features. Because of the unspecific heterogeneous clinical features of the disease, a delay in diagnosis is common. Secondary, inflammatory (AA type) amyloidosis has infrequently been observed in CVID patients. Based on our case observation and a critical review of the literature, we suggest that NLRP12 mutations might account for a small fraction of CVID patients with severe auto-inflammatory complications.

MATERIALIEN
Produktnummer
Marke
Produktbeschreibung

Sigma-Aldrich
Ribonukleinsäure aus Torulahefe, Type VI
Sigma-Aldrich
Ribonukleinsäure aus Backhefe (S. cerevisiae)
Sigma-Aldrich
Ribonukleinsäure aus Torulahefe, Type IX
Sigma-Aldrich
Ribonukleinsäure aus Torulahefe, core, Type II-C
Ribonucleinsäure, European Pharmacopoeia (EP) Reference Standard